ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Instill Bio Inc

Instill Bio Inc (TIL)

58.00
-3.25
(-5.31%)
Closed 03 October 6:00AM
58.00
0.00
( 0.00% )
Pre Market: 11:25PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
58.00
Bid
56.00
Offer
57.20
Volume
939
0.00 Day's Range 0.00
6.07 52 Week Range 92.00
Market Cap
Previous Close
58.00
Open
-
Last Trade
1
@
57.06
Last Trade Time
23:21:53
Financial Volume
-
VWAP
-
Average Volume (3m)
240,762
Shares Outstanding
6,503,913
Dividend Yield
-
PE Ratio
-2.42
Earnings Per Share (EPS)
-24
Revenue
-
Net Profit
-156.09M

About Instill Bio Inc

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TI... Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Dover, Delaware, USA
Founded
-
Instill Bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TIL. The last closing price for Instill Bio was US$58. Over the last year, Instill Bio shares have traded in a share price range of US$ 6.07 to US$ 92.00.

Instill Bio currently has 6,503,913 shares in issue. The market capitalisation of Instill Bio is US$377.23 million. Instill Bio has a price to earnings ratio (PE ratio) of -2.42.

TIL Latest News

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation...

Dell, Palantir, and Erie Will Be Added to the S&P 500; Boeing Avoids Strike; Apple Event Takes Place Today

Dell Technologies (NYSE:DELL), Palantir Technologies (NYSE:PLTR), Erie Indemnity (NASDAQ:ERIE), American Airlines (NASDAQ:AAL), Etsy (NASDAQ:ETSY), Bio-Rad Laboratories (NYSE:BIO) – S&P...

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-10.95-15.881073241568.9571.9756.2112589863.89577406CS
444.005314.43372633113.9959213.7563661260.73864194CS
1248.18490.6313645629.82929.724076255.73720463CS
2647.68462.01550387610.32929.6211648653.94769927CS
5250.04628.643216087.96926.0718551622.14246957CS
156-319.8-84.6479618846377.8464.36.0748700282.77316399CS
260-22-27.580589.86.07408295116.2699642CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 10.74
(0.00%)
223.84k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 63.55
(0.00%)
0
AADIAadi Bioscience Inc
US$ 1.96
(0.00%)
1
AACGATA Creativity Global
US$ 0.8955
(0.00%)
592
AALAmerican Airlines Group Inc
US$ 10.74
(0.00%)
223.84k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 63.55
(0.00%)
0
AADIAadi Bioscience Inc
US$ 1.96
(0.00%)
1
AACGATA Creativity Global
US$ 0.8955
(0.00%)
592
ELABElevai Labs Inc
US$ 0.0852
(0.00%)
168.36M
PEGYPineapple Energy Inc
US$ 0.1149
(0.00%)
98.7M
MLGOMicroAlgo Inc
US$ 0.31
(0.00%)
41.06M
CDTConduit Pharmaceuticals Inc
US$ 0.095
(0.00%)
27M
XPONExpion360 Inc
US$ 0.0466
(0.00%)
10.89M

TIL Discussion

View Posts
Monksdream Monksdream 3 weeks ago
TIL new 52 week high
👍️0
Monksdream Monksdream 3 weeks ago
TIL new 52 week high
👍️0
TheFinalCD TheFinalCD 3 weeks ago
$TIL When you buy things for extremely cheap, as was the case here with one of the largest NAV discounts I've ever seen, you are getting free and open ended call options on unexpected upside materializing. +25% today but still at a discount to NAV and now offering far more… https://t.co/Bl40o2QOwi— Jake LaMotta (@ragingbullcap) September 9, 2024
👍️0
TheFinalCD TheFinalCD 3 weeks ago
23.72= WOW on VERY LOW VOL
👍️0
Monksdream Monksdream 4 weeks ago
TIL under $15
👍️0
Monksdream Monksdream 12 months ago
TIL new 52 week low
👍️0
gail gail 2 years ago
lol
👍️0
Ettore Bastianini Ettore Bastianini 2 years ago
Damn you only held for 30 minutes lol it's at 90c now and they just released news that they have enough cash for the next 4 years. Missed out on almost a 1 bagga in a month
👍️0
gail gail 2 years ago
im back out, lol. was worth a try.
👍️0
gail gail 2 years ago
grabbed some here too, hi e.z.!
👍️0
makinezmoney makinezmoney 2 years ago
$TIL: Bouncing today at 0.60


Lots of gap up room on the chart if it wanna



GO $TIL
👍️0
Watts Watt Watts Watt 2 years ago
The light at the end of the tunnel is finally making its way through by way of thin, sure rays.
👍️0
bandit007 bandit007 2 years ago
Bottom bounce
👍️0
Watts Watt Watts Watt 3 years ago
A note about Instil's Competition, Iovance and their latest news:



http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210923:nGNX2fMDMm&default-theme=true
👍️0
Watts Watt Watts Watt 3 years ago
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210916:nGNX799jFk&default-theme=true

DALLAS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced today that a subset analysis of treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients with checkpoint inhibitor-refractory advanced cutaneous melanoma was presented today at the 2021 European Society for Medical Oncology (ESMO) Congress, taking place virtually from September 16-21, 2021.

Among the 12 patients featured in this subset analysis who had disease progression following treatment with a PD-1 inhibitor, all were also resistant to CTLA-4 inhibition with ipilimumab. Seven (58%) patients achieved an objective response, with 1 (8%) achieving a complete response. With a median duration of follow-up of 45.5 months, the median overall survival was 21.3 months with nearly half of patients experiencing long term survival. Side effects of treatment were largely transient, manageable with supportive care, and generally attributable to the lymphodepleting chemotherapy regimen and post-TIL high-dose IL-2 treatment. Outcomes in this highly treatment-refractory subgroup were similar to those observed in all 21 treated patients, with high response rates and an expected safety profile.

“The results of this analysis of a difficult-to-treat subgroup of patients further demonstrate that TIL therapy may offer benefit to patients with advanced melanoma once standard treatments have failed,” said Zachary Roberts, M.D., Ph.D., Chief Medical Officer of Instil Bio. “We eagerly anticipate building on these results in DELTA-1, our Phase 2 study of ITIL-168 in patients with advanced melanoma.”

Poster Presentation Details
Title: Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma
Poster Session: ePoster Display
Poster Number: 1058P

About ITIL-168

ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. Made from each patient’s digested and cryopreserved tumor, ITIL-168 is a TIL cell therapy manufactured to offer an unrestricted T cell receptor (TCR) repertoire. Instil’s proprietary, optimized, and scalable manufacturing process has been designed to capture and preserve the maximum diversity of each patient’s TILs. By collecting the patient’s tumor and immediately processing and then cryopreserving it, our process offers significant scheduling flexibility for patients and physicians at the time of both tumor resection and TIL treatment. In addition to DELTA-1, Instil plans to investigate ITIL-168 in additional solid tumor indications in Phase 1 clinical trials beginning in 2022.

About DELTA-1

DELTA-1 is a global, multicenter Phase 2 clinical trial of ITIL-168 in adult patients with advanced melanoma. Using an open-label, single-arm design, the main study cohort will evaluate the efficacy and safety of ITIL-168, when administered after a 5-day course of lymphodepleting chemotherapy and followed by up to 8 doses of high-dose interleukin-2 (IL-2), in patients whose cancer has progressed following a PD-1 inhibitor and, if positive for a BRAF-activating mutation, a BRAF inhibitor. Approximately 80 subjects are planned for enrollment and treatment in Cohort 1. Cohort 2 is anticipated to enroll approximately 25 subjects and is designed to evaluate the efficacy and safety of the regimen in patients who required discontinuation of PD-1 inhibitor(s) due to unacceptable toxicity, regardless of best overall disease response. Cohort 3 is also anticipated to enroll approximately 25 subjects and will evaluate efficacy and safety in patients whose best ongoing response to PD-1 inhibitor(s) is stable disease. Patients in Cohorts 2 and 3 whose cancer expresses a BRAF-activating mutation will be required to have experienced disease progression following BRAF inhibitor therapy. The primary endpoint of DELTA-1 is the objective response rate (ORR) according to RECIST v1.1 as assessed by independent central review. Secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety.

About Instil Bio

Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, including the design and enrollment of the DELTA-1 clinical trial, the timing of initiating clinical trials, the timing of reporting of data and the timing of regulatory submissions, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, whether, if approved, these product candidates will be successfully distributed and marketed, and our clinical manufacturing capabilities. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the SEC on August 12, 2021, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Contacts:

Brendan Payne
Stern Investor Relations
1-212-362-1200
brendan.payne@sternir.com

Media Contact:
1-833-446-7845 Ext. 1009
mediarelations@instilbio.com
👍️0
Watts Watt Watts Watt 3 years ago
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma

Additional Cohorts: ITIL-168 clinical trial expanded during IND review process with two additional cohorts, broadening the study target population

DALLAS, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate DELTA-1, a global Phase 2 clinical trial of ITIL-168 in patients with advanced melanoma whose disease has relapsed after a PD-1 inhibitor and, if positive for a BRAF-activating mutation, a BRAF inhibitor.

The DELTA-1 trial was expanded during the IND review process, in consultation with FDA, to include additional populations of patients with advanced melanoma. Cohorts 2 and 3 will enroll patients who discontinued PD-1 inhibitor therapy due to intolerable toxicity and patients who had an unsatisfactory response to prior PD-1 inhibitor but have not yet experienced disease progression, respectively. Topline safety and efficacy results are expected in 2023 and, if positive, are anticipated to support the submission of a biologics license application (BLA) to the FDA in 2023 and a Marketing Authorization Application (MAA) to the European Medicines Agency in 2024.

“The IND clearance for the DELTA-1 Phase 2 clinical trial is a testament to the talent, experience and devotion of the Instil Bio team,” said Bronson Crouch, Chief Executive Officer of Instil. “Motivated by patients in need, our organization will develop ITIL-168 commercially as we expand our clinical programs with current and next-generation therapies.”

“This achievement reflects the depth of cell therapy experience, scientific talent and focused execution of our organizations in both the U.S. and U.K.,” said Vijay Chiruvolu, Ph.D., Chief Technical Officer of Instil. “Additionally, the development of the product release plan, encompassing the innovative potency assay as part of QC release as well as the comprehensive characterization strategy, was built on expertise from our broad, cross-functional team including research, process development, analytical sciences and translational medicine.”

Zachary Roberts, M.D. Ph.D., Chief Medical Officer of Instil added, “We are pleased to begin this clinical trial of ITIL-168 in an area of marked unmet medical need. Furthermore, the inclusion of additional cohorts of patients who have not been systematically studied with TIL therapy provides us with the opportunity to learn about the potential role of ITIL-168 in other populations who lack effective therapies.”

About ITIL-168

ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. Made from each patient’s digested and cryopreserved tumor, ITIL-168 is a TIL cell therapy manufactured to offer an unrestricted T cell receptor (TCR) repertoire. Instil’s proprietary, optimized, and scalable manufacturing process has been designed to capture and preserve the maximum diversity of each patient’s TILs. By collecting the patient’s tumor and immediately processing and then cryopreserving it, our process offers significant scheduling flexibility for patients and physicians at the time of both tumor resection and TIL treatment. In addition to DELTA-1, Instil plans to investigate ITIL-168 in additional solid tumor indications in Phase 1 clinical trials beginning in 2022.

About DELTA-1

DELTA-1 is a global, multicenter Phase 2 clinical trial of ITIL-168 in adult patients with advanced melanoma. Using an open-label, single-arm design, the main study cohort will evaluate the efficacy and safety of ITIL-168, when administered after a 5-day course of lymphodepleting chemotherapy and followed by up to 8 doses of high-dose interleukin-2 (IL-2), in patients whose cancer has progressed following a PD-1 inhibitor and, if positive for a BRAF-activating mutation, a BRAF inhibitor. Approximately 80 subjects are planned for enrollment and treatment in Cohort 1. Cohort 2 is anticipated to enroll approximately 25 subjects and is designed to evaluate the efficacy and safety of the regimen in patients who required discontinuation of PD-1 inhibitor(s) due to unacceptable toxicity, regardless of best overall disease response. Cohort 3 is also anticipated to enroll approximately 25 subjects and will evaluate efficacy and safety in patients whose best ongoing response to PD-1 inhibitor(s) is stable disease. Patients in Cohorts 2 and 3 whose cancer expresses a BRAF-activating mutation will be required to have experienced disease progression following BRAF inhibitor therapy. The primary endpoint of DELTA-1 is the objective response rate (ORR) according to RECIST v1.1 as assessed by independent central review. Secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety.

About Instil Bio

Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing TIL therapies for the treatment of patients with cancer and as an innovation platform for next generation therapies. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, including the design and enrollment of the DELTA-1 clinical trial, the timing of initiating clinical trials, the timing of reporting of data and the timing of regulatory submissions, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, whether, if approved, these product candidates will be successfully distributed and marketed, and our clinical manufacturing capabilities. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the SEC on August 12, 2021, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Contacts:

Brendan Payne
Stern Investor Relations
1-212-362-1200
brendan.payne@sternir.com

Media Contact:
1-833-446-7845 Ext. 1009
mediarelations@instilbio.com

http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210913:nGNXbNbylw&default-theme=true
👍️0
Almosthere Almosthere 3 years ago
There goes bull shit TIL back into its gutter again.

Don’t be surprised when you see this continue to tumble in the wake of the pandemic!

Here’s the truth about the pandemic and it’s devastation:

https://english.kyodonews.net/news/2021/09/4f8dea9c30e2-coronavirus-pandemic-latest-sept-9-2021.html

Better sell before TIL tanks further and you loose your arse!

IMHO

P.S. I’ll be sure to send updates come Monday morning.
👍️0
Almosthere Almosthere 3 years ago
https://khn.org/morning-breakout/covid-outlook-getting-worse-for-kids/

Down she goes!!! Time to sell before the floor drops out of this stock.

IMHO
👍️0
Almosthere Almosthere 3 years ago
This bullshit stock is sure tank back down into the single digits as the pandemic grows worse.

School year is just starting and covid effects will sink this stock again!

https://www.google.com/amp/s/amp.cnn.com/cnn/us/live-news/coronavirus-school-vaccine-updates-09-10-21/index.html

Think your safe in here, think again!!

IMHO
👍️0
Watts Watt Watts Watt 3 years ago
https://ih.advfn.com/stock-market/NASDAQ/instill-bio-TIL/stock-news/85817548/instil-bio-reports-second-quarter-2021-financial-r
👍️0
Watts Watt Watts Watt 3 years ago
Below are 2nd QUARTER 2021 Results:

https://ih.advfn.com/stock-market/NASDAQ/instill-bio-TIL/stock-news/85817548/instil-bio-reports-second-quarter-2021-financial-r
👍️0
Watts Watt Watts Watt 3 years ago
Below are FIRST QUARTER RESULTS:

https://finance.yahoo.com/news/instil-bio-reports-first-quarter-110000823.html?.tsrc=rss

Thursday, Aug 12 will be SECOND QUARTER RESULTS:

??
👍️0
Watts Watt Watts Watt 3 years ago
Does anyone know when TIL will be releasing its Earnings Report?

Okay, I will answer my own question:

Thursday, August 12, 2021
👍️0
Watts Watt Watts Watt 3 years ago
Perhaps we confirmed a bottom at 14.61
👍️0
Watts Watt Watts Watt 3 years ago
Beginning to see some downward action...in just a week or so, from USD 20 down to USD 14.61 today.

What does this portend?

Insiders are locked out from trading.

This means that shorters have come in to wreak havoc.
👍️0
Watts Watt Watts Watt 3 years ago
Notice to all Instil Bio Inc (TIL) investors:

Recently, IHUB erroneously linked news concerning a CANADIAN company,
TILL CAPITAL Corporation, trading on the Toronto Stock Exchange Venture TSXV, similarly listed as TIL.

Be sure to distinguish the two companies, as they have absolutely know connection or financial interest with each other.

TIL (Instil Bio) trades on NASDAQ and is a biotech firm.

The Canadian Company is a mining company.

Thank you for your attention!
👍️0
Watts Watt Watts Watt 3 years ago
Interesting approach to attacking melanoma tumors via harvesting, digestion, culturing and augmentation and re-insertion of patient's own TILS. The key, as always, will be FDA approval of trials in the US.
👍️0

Your Recent History

Delayed Upgrade Clock